T-Therapeutics, a UK biotech developing next-generation T cell receptor (TCR) therapies for cancer and autoimmune diseases, has expanded its Series A round with an additional €27.5 million ($32 million) in funding.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?